A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.
Pegylated Interferon Leads to High Response Rates in Essential Thrombocythemia and Polycythemia Vera After...
According to results of a phase II study published in Blood, treatment with pegylated-interferon-α (PEG-rIFN-α) was associated with an overall response rate (ORR) of...
From ASH Meeting on Hematologic Malignancies: How would you treat this patient with high-grade...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
Estimated Prevalence of JAK2 V617F Mutations High in General Danish Population
The driver mutation JAK2 V617F and Calreticulin (CALR) mutations constitute major diagnostic criteria of myeloproliferative neoplasms (MPNs), and, while JAK2 V617F has been detected...
Fedratinib Now Approved for Primary or Secondary Myelofibrosis
The U.S. Food and Drug Administration (FDA) has approved fedratinib to treat intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis....
Evaluating Risk of Developing Second Cancers in Patients With Ph-Negative Myeloproliferative Neoplasms
According to results from a nested case-control study, patients with Philadelphia chromosome (Ph)–negative myeloproliferative neoplasms (MPNs) are at an increased risk of developing secondary...
Exploring New Settings for Tagraxofusp: CMML and Myelofibrosis
In late 2018, the U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children with blastic plasmacytoid dendritic cell neoplasm,...
Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm
Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...
Evaluating PRM-151 in Patients With Myelofibrosis Resistant or Intolerant to Ruxolitinib
According to results from a double-blind, phase II study, PRM-151 improved bone marrow fibrosis grade, transfusion dependence, and symptoms in a cohort of patients...
Exploring Safety and Efficacy of 5F9 and Azacitidine in AML and MDS
Watch our interview with David Sallman, MD.In initial results from a phase Ib trial presented at the 2019 American Society of Clinical Oncology annual...
Naveen Pemmaraju: A New Option for Myelofibrosis?
Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
